| INTRODUC TI ON
According to 2014 epidemiological data, about 8.3% of world adult population (about 382 million people) suffers from primary type 2 diabetes (T2DM).
1 T2DM patients were more likely to develop microvascular and macrovascular complications 2 that lead to die of cardiovascular and cerebrovascular diseases. 3 It has been well known that systematic oxidative stress may be enhanced by hyperglycemia and hyperlipidemia in patients with T2DM, which result in the over generation of lipid peroxides, and subsequently, contribute to microangiopathy pathogenesis and atherothrombosis. It is the pathogenic mechanisms underlying the generation of microvascular complications in diabetic patients. 4, 5 oxLDL are able to cause endothelial inflammation and endothelial dysfunction. 6,7 β2-glycoprotein I (β2-GPI) is a 50-kDa plasma protein that binds to negatively charged molecules, including phospholipids and heparin, and to plasma membranes of activated platelets and apoptotic cells on which phosphatidylserine is exposed. 7 oxLDL can bind to β2-GPI and form oxLDL/β2-GPI complexes, [8] [9] [10] prompting macrophages to phagocytize oxLDL through the β2-GPI autoantibody-mediated pathway, thus inducing the formation of foam cells that participate in atherosclerosis and vascular diseases.
It has been demonstrated that the serum oxLDL/β2-GPI complexes were significantly increased in patients who had microvascular diseases such as chronic inflammatory diseases and some autoimmune diseases, [11] [12] [13] [14] as well as with macrovascular diseases [15] [16] [17] and T2DM. 11, 18 It was also indicated that non-autoimmune diseases patients comorbid with premature or accelerated stages of atherogenesis had elevated levels of oxLDL/β2-GPI complexes in vivo, indicating its potential role in vascular thromboembolism. 15, 19, 20 The elevated oxidative stress may give rise to damage of endothelial cells and vascular dysfunction in T2DM patients. Various mechanisms are involved in this process, especially including the promotion of microvascular thromboembolism, which leads to the generation and progression of diabetic microangiopathy. 21 Previous study revealed that T2DM patients who taking statins to lower the cholesterol were showed decreased levels of serum oxLDL/β2-GPI complexes, which were consistent with the antithrombotic and antioxidant effectiveness of statins therapy. 11 It was suggested that the increase of oxLDL/β2-GPI complexes levels might be contributed to the oxidative stress-induced and LDL-mediated atherogenic modification.
However, few studies had confirmed the direct correlation between serum oxLDL/β2-GPI complexes and ox-LDL levels in T2DM patients. Moreover, it still needed to be further studied about the differences in serum oxLDL/β2-GPI complexes levels between T2DM patients with and without diabetic microvascular complications, as well as the association between oxLDL/ β2-GPI complexes and microangiopathy generation. It could be hypothesized that the oxLDL/β2-GPI complexes participate in the development of microvascular complications in T2DM patients.
Therefore, we aimed to determine whether the levels of oxLDL/ β2-GPI complexes correlate with diabetic microvascular complications in T2DM patients and to clarify the clinical significance of oxLDL/β2-GPI complexes in predicting the occurrence of diabetic microvascular complications. 
| MATERIAL S AND ME THODS

| Study subjects
| oxLDL/β2-GPI complexes measurement
The blood samples were collected 12 hours after fasting. The serum was rapidly isolated by a 1509 g centrifugal machine for 15 minutes, and preserved at −80°C environment until use. The oxLDL/β2-GPI complexes levels was measured by the sandwich enzyme-linked immunosorbent assay, as previously described. 18 The polyclonal antibody against human β2-GPI was coated onto 96-microwell plates and the polyclonal anti-human apoprotein B antibody was used as the detection antibody. 4 Serum sampled (500 μL) containing 10 μmol/L MgCl 2 were incubated for 2 hours at room temperature. Then, polyethylene glycol (PEG) was added and the samples were incubated at 4°C overnight. The samples underwent 16 770 g centrifugation for 20 minutes.
The 500 μL washing solution, which contained 0.05% Tween-20 and 0.5% gelatin dissolved in 0.01 mol/L PBS, was used for resuspension of the precipitates. Antihuman β2-GPI antibody was added to microwells at 2.5 μg/mL (100 μL/well) and incubated at 37°C for 2 hours and then transferred to 4°C environment overnight.
Samples diluted at 1:40 (re-suspended in PBST containing gelatin) or serial reference sera were administrated to the wells. After blocking with 0.01 mol/L PBS that containing 1% gelatin, the samples were incubated for 2 hours. Then, the wells were incubated with BSA for 2 hours. Standard oxLDL/β2-GPI complexes were administrated in the wells and underwent incubation at 4°C overnight in order to obtain the standard curve. HRP-labeled goat anti-rabbit LDL polyclonal antibody was administrated in the wells and then incubated at room temperature for 3 hours. Color was developed with TMBUS substrate, and the reaction was stopped by 2 mol/L sulfuric acid.
The absorbance at 450 nm was obtained with a microplate reader.
Between each step, the wells were washed 3 times with 0.05%
Tween-20 dissolved in PBS. The reference serum oxLDL/β2-GPI complexes was made using fresh plasma samples from a collection of 60 healthy subjects. Serum oxLDL/β2-GPI complexes concentration (expressed in U/mL) was calculated against a reference curve built with serial dilutions of the reference serum. Intra-and inter-assay coefficients of variation were all <15%.
| Biochemistry
Fasting plasma glucose (FPG), 2-h postprandial blood glucose (2hPBG), total cholesterol (TC), HDL-cholesterol, LDL-cholesterol, and triglycerides (TG) were determined using a ROCHE Modular P800 Automatic
Biochemical Analyzer (Roche Diagnostics, Basel, Switzerland). Serum insulin levels were measured using a Siemens centaur XP Chemiluminescence
Immune Analyzer (Siemens, Erlangen, Germany). HbA1c was measured using a Variant II Turbo (Bio-Rad, Hercules, CA, USA).
| Statistical analysis
The distribution of continuous data was assessed using the Table 1 shows the characteristics of the subjects. There were no differences in age or gender among the 3 groups (all P > 0.05). BMI of patients with T2DM were higher than that of control group (all P < 0.05). In comparison with the control group, patients with T2DM had higher TC, TG, LDL-C, FBG 2hPG, HbA1c, FINS, and lower HDL-C 
| RE SULTS
| Characteristics of the subjects
| Serum oxLDL/β2-GPI complexes and oxLDL
Compared with the control group (oxLDL/β2-GPI complexes:
0.79 ± 0.15 U/mL; oxLDL: 27.85 ± 5.32 mmol/L), serum oxLDL/β2-GPI complexes and oxLDL levels were higher in T2DM patients (all P < 0.05). Furthermore, serum oxLDL/β2-GPI complexes and oxLDL levels were higher in T2DM patients accompanied by diabetic microvascular complications (oxLDL/β2-GPI complexes: 1.10 ± 0.18 U/mL; oxLDL: 48.12 ± 7.24 mmol/L), compared with T2DM patients without any diabetic microvascular complication (oxLDL/β2-GPI complexes: 0.98 ± 0.16 U/mL; oxLDL: 41.45 ± 6.81 mmol/L) ( Table 1 ).
| Associations among oxLDL/β2-GPI complexes, ox-LDL levels and other glucose and lipid metabolism parameters in T2DM patients
To investigate the association among oxLDL/β2-GPI complexes,
ox-LDL levels and other glucose and lipid metabolism parameters,
Spearman's correlation analyses were performed. Similar association among oxLDL/β2-GPI complexes, oxLDL and other glucose and lipid metabolism parameters were also observed in T2DM patients with or without microvascular complications (data not shown); therefore, we combined all these T2DM patients for further analyses (n = 300).
Of all T2DM patients, the oxLDL/β2-GPI complexes levels were positively related to the TC (r = 0.513, P = 0.002) and TG (r = 0.456, P = 0.005) and oxLDL (r = 0.752, P < 0.001). The oxLDL levels were positively related to the TC (r = 0.486, P = 0.001) ( Table 2 ). To further investigate the independent contribution of the different variables to oxLDL/β2-GPI complexes, we conduct a stepwise multivariable linear regression analysis, and the model included above-mentioned lipid parameters, patients' characteristics such as age, gender, BMI, HbA1c, and microvascular complications. The variables that remained significantly associated with oxLDL/β2-GPI complexes were oxLDL (β = 0.568, P < 0.001), TC (β = 0.312, P = 0.013) and microvascular complications (β = 0.205, P = 0.027), which accounted for 58.3% of the variation of the level of oxLDL/β2-GPI complexes in all these T2DM patients (R 2 =0.583).
| Associations of oxLDL/β2-GPI complexes and oxLDL with diabetic microvascular complications in T2DM patients
The age, gender, BMI, TC, TG, HDL-C, LDL-C, and HbA1c were used to be adjusted in the Logistic regression analysis. Table 3 ).
In the multivariate analysis, the oxLDL/β2-GPI complexes 
| D ISCUSS I ON
In this study, we found that in comparison with T2DM patients without diabetic microvascular complications and healthy controls, serum oxLDL/β2-GPI complexes levels and oxLDL were obviously increased in T2DM patients accompanied by diabetic microvascular complications (including diabetic retinopathy, nephrology and neuropathy). Variables that remained significantly associated with oxLDL/β2-GPI complexes were oxLDL, TC, and microvascular complications, which accounted for 58.3% of the variation of the level of oxLDL/β2-GPI complexes in T2DM patients. The elevation of oxLDL/β2-GPI complexes and oxLDL were independently correlated with microvascular complications in T2DM patients.
The β2-GPI is a protein superfamily member that controlling the plasma complement, which is available to combine lipoproteins and other matters with negative charge. 8, 20 ox-LDL could interact with β2-GPI through 7-ketocholesterol, and its w-carboxyl acyl chain could form covalent linkage, to form oxLDL/β2-GPI complexes in vitro. 8, 20 It was found in patients involving atherothrombotic vascular events that oxLDL/β2-GPI complexes were present through the circulating blood. 11, 15, 20 Here, we found that serum ox-LDL and β2-GPI-LDL levels were obviously elevated in both groups of T2DM
patients. It was already recognized that glucolipid metabolic dysregulation promoted the premature atherosclerosis and accelerated the thrombosis in T2DM patients. 4, 8 It was also widely accepted that the ox-LDL was the major lipoproteins involved in atherogenic effects. 23 The oxLDL/β2-GPI complexes were probably played a role in accelerating the intracellular ox-LDL accumulation when the β2-GPI was presented, which was induced through anti-β2-GPI antibodies.
It also promoted the formation of foam cells. 24 This indicated the role of oxLDL/β2-GPI complexes in the atherosis generation. Also, the β2-GPI was colocalized with the ox-LDL in atherosclerotic lesions of the arterial intima. 25 Therefore, elevation of both oxLDL/ β2-GPI complexes and ox-LDL could contribute to the mechanisms of atherothrombotic events in T2DM patients. It was worth noting that a significant correlation was observed between the serum β2-GPI-LDL and ox-LDL levels in T2DM patients. Moreover, ox-LDL was observed to be the independent factor that determining the β2-GPI-LDL levels. During detection of β2-GPI-LDL, the sandwich ELISA could detect other forms of modified LDL (eg, acetylated LDL, and MDA-modified LDL), β2-GPI complexes with oxidized LDL, and native LDL (if there existed), the correlation between ox-LDL and β2-GPI-LDL, but not native LDL (reflected by LDL-C), may offer direct evidence that β2-GPI was preferentially interplayed with ox-LDL.
Thus, high levels of β2-GPI-LDL could be resulted from increased ox-LDL levels. Elevated β2-GPI-LDL may be the serum marker of 
TA B L E 3 Univariate and multivariate
Logistic regression for the association of oxLDL/β2-GPI and oxLDL in patients with T2DM with or without diabetic microvascular complication F I G U R E 1 ROC curve was constructed to verify the association of oxLDL/β2-GPI with the presence of diabetic microvascular complications in T2DM patients increased LDL oxidation level. In addition, it was accessible to detect the binding of β2-GPI complexes to the LDL particles, which had various oxidative degree, in different sites (regardless of minimally ox-LDL or extensively ox-LDL). Therefore, compared with the previous β2-GPI/ox-LDL technology, 8, 11, 20 the detection range of β2-GPI-LDL assay was acceptable and it would better reflect the pathogenic process of LDL levels. Also, the same antibody could target the human β2-GPI and detect the β2-GPI-Lp(a) levels in both coronary artery disease and T2DM patients. 26, 27 Glucolipid metabolic dysregulation, which elicited by insulin resistance, may accelerate the disruption of oxidant/antioxidant balance in T2DM patients, resulting in elevation of reactive oxygen species (ROS) and lipids peroxidation, and further promoted the occurrence of microvascular complications. 21 Additionally, lipid deposition in the microcirculation could also play a role in the deterioration of microangiopathy. 4, 5, 21 Here, both β2-GPI-LDL and ox-LDL levels were indicated to increase more significantly in T2DM patients who had diabetic microvascular complications than in those without. Previous study had shown that oxidative stress elevation could be observed in the early stage of diabetes occurrence and development. 21 Particularly, the ox-LDL could play as a sensitive marker. 23, 28 Therefore, the ox-LDL levels still significantly increased in patients without diabetic microvascular complications. The superabundant lipid peroxides production in blood circulation may aggravate the cellular oxidative injuries and endothelial dysfunction elicited by systematic oxidative stress. They could promote the occurrence and development of microvascular thromboembolic events in T2DM patients. 23 Surprisingly, both β2-GPI-LDL and ox-LDL were associated with microangiopathy occurrence in T2DM patients while only the ox-LDL was showed obvious correlation with T2DM occurrence that had no complications. In vivo, high ox-LDL levels represented the enhanced oxidative stress reaction. So, the oxidant/antioxidant dysregulation responses in diabetic patients may firstly result in the increased ox-LDL levels and further lead to β2-GPI-LDL levels elevation.
Therefore, in comparison with the β2-GPI-LDL, the ox-LDL level could be showed more obvious associated with the T2DM without complications (during early stage of diabetic patients). It was reported that the ox-LDL had enhanced cytotoxic effects on both smooth muscle cells and vascular endothelial cells, which played a role in the generation of microangiopathy in diabetics. 23, 28 High levels of β2-GPI-LDL, which was resulted from oxidative lipids storage, may represent oxidant/antioxidant systems unbalance.
More obvious association was observed between β2-GPI-LDL and the presence of diabetic microvascular complications occurrence in T2DM patients.
The study has several limitation, including the small cohort size and the recruitment of patients from a single center. In addition, the study was not designed to address any causality issue. These results should be confirmed with multicenter studies and with a larger number of patients. The findings should be interpreted with caution and considered as hypotheses generating.
This study demonstrated an increase in serum oxLDL/β2-GPI complexes and oxLDL levels in T2DM patients, especially in patients accompanied by diabetic microvascular complications. The oxLDL/β2-GPI complexes and oxLDL levels were independently correlated in T2DM patients. Elevation of oxLDL/β2-GPI complexes levels might be associated with the occurrence of microvascular complications. These results may provide valuable information for clinicians to understand the role of circulating oxLDL/β2-GPI complexes in the pathogenesis of T2DM and diabetic microvascular complications.
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